NIKKEI 225
38,626.84 -6.18 (-0.02%) HANG SENG
18,046.40 -288.92 (-1.58%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.50 +7.50 (+0.32%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,976.80 -664.31 (-1.29%)
Immuneering Corporation (IMRX)
After hours:
| Previous close | 1.4800 |
| Open | 1.4900 |
| Bid | 1.3900 x 200 |
| Ask | 1.4200 x 200 |
| Day's range | 1.3800 - 1.4900 |
| 52-week range | 1.3000 - 11.5250 |
| Volume | |
| Avg. volume | 395,138 |
| Market cap | 43.887M |
| Beta (5Y monthly) | -0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Immuneering to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will b
- GlobeNewswire
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Ei
- GlobeNewswire
Immuneering Recognizes Melanoma Awareness Month
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors harboring RAF or RAS mutations - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering
